Who are F-18-PSMA-1007's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Copper Cu 64 Dotatate, Radium-223, Tc-99m Pentetate, Rubidium-82, Fludeoxyglucose F 18 (FDG), PET Scan with [18F] VAT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/f-18-psma-1007.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

F-18-PSMA-1007 — Competitive Intelligence Brief

F-18-PSMA-1007 (F-18-PSMA-1007) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; PSMA-targeting PET imaging agent. Area: Oncology.

phase 3 Radiopharmaceutical; PSMA-targeting PET imaging agent PSMA (prostate-specific membrane antigen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

F-18-PSMA-1007 (F-18-PSMA-1007) — ABX advanced biochemical compounds GmbH. F-18-PSMA-1007 is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
F-18-PSMA-1007 TARGET	F-18-PSMA-1007	ABX advanced biochemical compounds GmbH	phase 3	Radiopharmaceutical; PSMA-targeting PET imaging agent	PSMA (prostate-specific membrane antigen)
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)
Radium-223	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
Tc-99m Pentetate	Tc-99m Pentetate	NYU Langone Health	marketed	Radiopharmaceutical diagnostic agent
Rubidium-82	Rubidium-82	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	marketed	PET radiopharmaceutical	Na+/K+-ATPase pump (myocardial uptake mechanism)
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; PSMA-targeting PET imaging agent class)

ABX advanced biochemical compounds GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). F-18-PSMA-1007 — Competitive Intelligence Brief. https://druglandscape.com/ci/f-18-psma-1007. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab